Loading
Lung Cancer Treatments and Mutations / Lung Cancer Diagnosis and Treatment · Journal article
American Journal of Clinical Oncology · September 7, 2026
Encouraging direction, but not yet definitive.
This meta-analysis pools single-arm data from four post-TKI, MET-selected NSCLC cohorts (n=338) to evaluate savolitinib plus osimertinib, reporting an ORR of 53.9% (95% CI 45.1–62.4%) and DCR of 85.2% (79.2–89.8%), with grade ≥3 adverse events in 48.8%. The authors acknowledge that reliance on single-arm evidence limits conclusions and call for randomized trials to confirm benefit.
Meta-analysis of randomized controlled trials and prospective single-arm studies. Patients with EGFR-mutant, MET-aberrant advanced NSCLC enrolled in included trials; primary analysis restricted to post-TKI, MET-selected cohorts.. Intervention: Savolitinib combined with osimertinib. n = 338.
Pooled ORR in post-TKI, MET-selected cohorts was 53.9% (95% CI: 45.1–62.4%) across 338 patients from 4 cohorts Disease control rate was 85.2% (95% CI: 79.2–89.8%) 6-month PFS rate was 59.8%
Grade ≥3 adverse events occurred in 48.8% of patients
Clinicians should view this as early supporting evidence for combined savolitinib and osimertinib in select MET-aberrant NSCLC patients, particularly those progressing on prior TKI therapy. However, the absence of a randomized control arm and reliance on surrogate endpoints (ORR, DCR) mean treatment decisions should await confirmatory randomized trial data before widespread adoption.
Meta-analysis of single-arm cohorts showing encouraging efficacy (ORR 53.9%) and manageable safety, but limited by lack of randomized comparator and reliance on surrogate endpoints; requires confirmatory RCT evidence.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should view this as early supporting evidence for combined savolitinib and osimertinib in select MET-aberrant NSCLC patients, particularly those progressing on prior TKI therapy. However, the absence of a randomized control arm and reliance on surrogate endpoints (ORR, DCR) mean treatment decisions should await confirmatory randomized trial data before widespread adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objectives: NSCLC is the leading cause of cancer-related mortality. While combined therapy including savolitinib and osimertinib appears promising, there exists a lack of comprehensive pooled evidence regarding its anti-oncological activity.: The objective of this study is to evaluate the efficacy and safety of combined therapy in patients with NSCLC. Methods: A comprehensive literature search was conducted in MEDLINE, the Cochrane Central Register of controlled trials, and ClinicalTrials.gov. Randomized controlled trials and prospective single-arm studies evaluating savolitinib combined with osimertinib were included. A random-effects single-arm meta-analysis of proportions was performed using logit transformation and inverse variance weighting, with restricted maximum likelihood (REML) estimation and Knapp-Hartung adjustment. Results were reported with a 95% CI, and heterogeneity was assessed using the I 2 statistic. Sensitivity analysis was conducted using the Freeman-Tukey transformation. Results: The primary analysis included 4 post-TKI, MET-selected combination cohorts (SACHI, SAVANNAH, and TATTON Part B; n=338) from 7 reports of 5 trials after de-duplication of overlapping data sets. First-line (FLOWERS) and MET-unselected (Yoh) cohorts were analyzed separately. The pooled objective response rate (ORR) was 53.9% (95% CI: 45.1-62.4), disease control rate (DCR) was 85.2% (79.2-89.8), 6-month progression-free survival (PFS) rate was 59.8%, and grade ≥3 adverse events occurred in 48.8% of patients. ORR estimates were consistent across studies and remained robust across sensitivity and subgroup analyses. Conclusions: Combined therapy shows encouraging results in selected MET, post-TKI NSCLC. However, reliance on single-arm data warrants further randomized controlled trials.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.